
  
    
      
        Introduction_NNP
        Most_JJS primary_JJ malignancies_NNS spread_VBP systemically_RB via_IN lymphatic_JJ dissemination_NN [_NN 1_CD ]_NN ._. For_IN
        example_NN ,_, the_DT finding_NN of_IN axillary_JJ nodal_NN metastases_NNS predicts_VBZ a_DT much_RB shorter_JJR disease-free_JJ
        survival_NN in_IN breast_NN cancer_NN [_NN 2_CD ]_NN ._. The_DT total_JJ nodal_NN tumor_NN burden_NN (_( number_NN of_IN affected_VBN nodes_NNS and_CC
        metastatic_JJ tumor_NN volume_NN )_) affects_VBZ prognosis_NN even_RB more_RBR severely_RB [_NN 3_CD ]_NN ._. Accurate_NNP lymph_NN node_NN
        staging_NN also_RB remains_VBZ a_DT cornerstone_NN in_IN choosing_VBG the_DT most_RBS appropriate_JJ therapy_NN for_IN a_DT given_VBN
        stage_NN ._. Therapeutic_NNP intervention_NN of_IN metastatic_JJ lymph_NN nodes_NNS [_NN 4_CD ]_NN ,_, prophylactic_JJ radiation_NN of_IN
        frequently_RB affected_VBN drainage_NN routes_NNS [_NN 5_CD ]_NN ,_, and_CC systemic_JJ therapies_NNS [_NN 6_CD ]_NN all_DT have_VBP been_VBN shown_VBN to_TO
        improve_VB survival_NN ._. Genetic_JJ profiles_NNS identifying_VBG metastatic_JJ tumors_NNS [_NN 7_CD ]_NN ,_, serum_NN biomarkers_NNS ,_, and_CC
        proteomic_JJ profiles_NNS are_VBP currently_RB being_VBG developed_VBN to_TO identify_VB patients_NNS at_IN risk_NN [_NN 8_CD ,_, 9_CD ]_NN ._. No_DT
        direct_JJ genetic_JJ profile_NN ,_, however_RB ,_, has_VBZ been_VBN demonstrated_VBN to_TO date_NN to_TO accurately_RB predict_VBP the_DT
        presence_NN of_IN human_JJ nodal_NN metastases_NNS in_IN a_DT given_VBN patient_NN ._. Rather_RB ,_, surgical_JJ approaches_NNS ,_, such_JJ as_IN
        sentinel_NN lymph_NN node_NN biopsy_NN or_CC lymph_NN node_NN dissection_NN ,_, are_VBP still_RB commonly_RB used_VBN ._. Careful_NNP
        histological_JJ analysis_NN includes_VBZ mapping_NN ,_, bisectioning_VBG ,_, and_CC rapid_JJ staining_VBG in_IN the_DT frozen_VBN
        tissue_NN laboratory_NN ._. Higher_JJR diagnostic_JJ accuracies_NNS can_MD be_VB achieved_VBN by_IN serial_NN sectioning_VBG (_( 50_CD
        μm_NN )_) and_CC by_IN immunohistochemical_JJ staining_VBG [_NN 10_CD ,_, 11_CD ]_NN ._.
        Noninvasive_NNP imaging_NN studies_NNS are_VBP commonly_RB used_VBN during_IN the_DT workup_NN of_IN primary_JJ malignancies_NNS ._.
        Typically_RB ,_, lymph_NN nodes_NNS are_VBP diagnosed_VBN by_IN tomographic_JJ techniques_NNS (_( computed_JJ tomography_NN [_NN CT_NNP ]_NN ,_,
        magnetic_JJ resonance_NN imaging_NN [_NN MRI_NNP ]_NN )_) as_IN malignant_JJ when_WRB their_PRP$ short_JJ axis_NNS is_VBZ >_NN 10_CD mm_NN in_IN size_NN
        [_NN 12_CD ]_NN ._. Such_JJ size_NN criteria_NNS ,_, however_RB ,_, have_VBP been_VBN shown_VBN to_TO be_VB unreliable_JJ [_NN 13_CD ]_NN ._. Similarly_RB ,_, the_DT
        detection_NN of_IN cancer_NN in_IN nonenlarged_JJ (_( occult_NN )_) nodes_NNS is_VBZ often_RB quite_RB low_JJ by_IN positron-emission_JJ
        tomography_NN (_( PET_NNP )_) and_CC single_JJ photon_NN emission_NN computed_JJ tomography_NN imaging_NN ._. For_IN example_NN ,_, small_JJ
        nodal_NN metastases_NNS (_( <_NN 5_CD mm_NN )_) are_VBP often_RB missed_VBN by_IN PET_NNP imaging_NN in_IN patients_NNS with_IN breast_NN cancer_NN
        [_NN 14_CD ]_NN ._. More_RBR recently_RB ,_, it_PRP has_VBZ become_VBN possible_JJ to_TO image_NN anatomic_JJ regions_NNS at_IN submillimeter_NN
        resolutions_NNS by_IN MRI_NNP ,_, with_IN excellent_JJ spatial_NN coverage_NN and_CC reduced_VBN motion_NN artifacts_NNS ._. The_DT
        development_NN [_NN 15_CD ,_, 16_CD ]_NN and_CC clinical_JJ introduction_NN of_IN lymphotropic_JJ magnetic_JJ nanoparticles_NNS has_VBZ
        been_VBN shown_VBN to_TO significantly_RB improve_VB diagnostic_JJ accuracies_NNS of_IN MRI_NNP for_IN nodal_NN staging_NN (_( LMRI_NNP )_)
        in_IN prostate_NN cancer_NN [_NN 17_CD ]_NN ._. These_DT nanoparticles_NNS serve_VBP as_IN probes_NNS for_IN lymphatic_JJ anatomy_NN and_CC
        function_NN and_CC enhance_VB tumor_NN detection_NN through_IN abnormal_JJ distribution_NN patterns_NNS in_IN malignant_JJ
        nodes_NNS [_NN 17_CD ,_, 18_CD ]_NN ._.
        Despite_IN the_DT advances_NNS of_IN LMRI_NNP for_IN cancer_NN staging_NN ,_, image_NN analysis_NN has_VBZ been_VBN challenging_VBG and_CC
        occasionally_RB controversial_JJ ._. Traditional_JJ analysis_NN has_VBZ been_VBN based_VBN on_IN a_DT reader_NN 's_POS
        identification_NN of_IN certain_JJ structural_JJ abnormalities_NNS that_WDT can_MD be_VB variable_JJ ,_, given_VBN differences_NNS
        in_IN acquisition_NN parameters_NNS and_CC interpretation_NN criteria_NNS [_NN 19_CD ,_, 20_CD ,_, 21_CD ]_NN ._. Furthermore_RB ,_, it_PRP has_VBZ been_VBN
        challenging_VBG to_TO quickly_RB and_CC accurately_RB analyze_VB large_JJ datasets_NNS generated_VBN by_IN LMRI_NNP ._.
        The_DT goal_NN of_IN the_DT current_JJ study_NN was_VBD to_TO develop_VB and_CC test_VB technologies_NNS that_WDT would_MD vastly_RB
        improve_VB the_DT accuracy_NN of_IN current_JJ LMRI_NNP nodal_NN staging_NN ._. Specifically_RB we_PRP set_VBD out_IN to_TO (_( a_DT )_)
        determine_VB whether_IN unique_JJ magnetic_JJ parameters_NNS existed_VBD and_CC could_MD be_VB used_VBN for_IN semiautomated_JJ
        image_NN analysis_NN and_CC (_( b_SYM )_) whether_IN the_DT technique_NN could_MD be_VB applied_VBN to_TO different_JJ primary_JJ cancers_NNS ._.
        Here_RB we_PRP provide_VBP the_DT first_JJ comprehensive_JJ analysis_NN of_IN tissue_NN parameters_NNS validated_JJ against_IN
        histopathology_NN as_IN an_DT end_NN point_NN ._.
      
      
        Methods_NNP
        
          Study_NNP Design_NNP
          The_DT Institutional_NNP Review_NNP Board_NNP approved_VBD the_DT current_JJ study_NN and_CC all_DT patients_NNS signed_VBD
          informed_VBN consent_NN ._. The_DT study_NN was_VBD divided_VBN into_IN a_DT learning_VBG (_(
          n_NN =_SYM 97_CD lymph_NN nodes_NNS with_IN known_VBN histopathology_NN )_) and_CC a_DT test_NN dataset_NN (_(
          n_NN =_SYM 216_CD lymph_NN nodes_NNS with_IN known_VBN histopathology_NN ;_: Table_NNP 1_LS )_) ._. Assignment_NNP
          into_IN datasets_NNS was_VBD done_VBN in_IN temporal_JJ fashion_NN ._. The_DT learning_VBG dataset_NN represented_VBD
          retrospective_NN cases_NNS at_IN outset_NN of_IN the_DT study_NN ,_, and_CC the_DT test_NN dataset_NN represented_VBD prospective_JJ
          cases_NNS collected_VBN during_IN a_DT 1_CD -_: y_NN interval_NN ._. In_IN the_DT learning_VBG set_VBN ,_, 55_CD %_NN of_IN the_DT nodes_NNS were_VBD benign_JJ ,_,
          and_CC 45_CD %_NN of_IN the_DT nodes_NNS were_VBD malignant_JJ ._. The_DT learning_VBG dataset_NN was_VBD obtained_VBN from_IN 36_CD patients_NNS
          (_( 24_CD male_JJ ,_, 12_CD female_JJ ,_, age_NN 28_CD –_NN 85_CD y_NN ,_, mean_VB 59_CD ._. 7_CD y_NN )_) with_IN histologically_RB proven_VBN primary_JJ
          genitourinary_JJ malignancies_NNS (_( prostate_NN ,_, 21_CD ;_: bladder_NN ,_, 9_CD ;_: testes_NNS ,_, 5_CD ;_: ureter_NN ,_, 1_LS )_) ._. All_DT patients_NNS
          completed_VBD the_DT MRI_NNP study_NN and_CC then_RB underwent_VBD surgical_JJ resection_NN (_(
          n_NN =_SYM 26_CD )_) and_CC /_NN or_CC nodal_NN biopsy_NN (_(
          n_NN =_SYM 10_CD )_) ._. The_DT investigated_VBN nodes_NNS had_VBD a_DT mean_JJ short_JJ axis_NNS diameter_NN of_IN 10_CD ._. 5_LS
          mm_NN (_( range_NN 3_CD –_NN 39_CD mm_NN )_) ._.
          The_DT test_NN dataset_NN was_VBD obtained_VBN from_IN 34_CD patients_NNS (_( 25_CD male_JJ ,_, nine_CD female_JJ ,_, age_NN 30_CD –_NN 82_CD y_NN ,_,
          mean_VB 58_CD ._. 9_CD y_NN )_) with_IN histologically_RB proven_VBN malignancies_NNS from_IN different_JJ primaries_NNS (_( Table_NNP 1_LS )_) ,_,
          including_VBG prostate_NN (_(
          n_NN =_SYM 18_CD )_) ,_, breast_NN (_(
          n_NN =_SYM 7_CD )_) ,_, penile_NN (_(
          n_NN =_SYM 4_LS )_) ,_, bladder_NN (_(
          n_NN =_SYM 2_LS )_) ,_, testes_NNS (_(
          n_NN =_SYM 2_LS )_) ,_, and_CC colon_NN (_(
          n_NN =_SYM 1_LS )_) ._. Seventy-nine_NNP percent_NN of_IN the_DT nodes_NNS were_VBD benign_JJ and_CC 21_CD %_NN of_IN the_DT
          nodes_NNS were_VBD malignant_JJ ._. The_DT nodes_NNS in_IN the_DT test_NN dataset_NN had_VBD a_DT mean_JJ short_JJ axis_NNS diameter_NN of_IN
          10_CD ._. 0_CD mm_NN (_( range_NN 3_CD –_NN 39_CD mm_NN )_) ._. Both_DT datasets_NNS included_VBD the_DT full_JJ spectrum_NN of_IN normal_JJ nodes_NNS to_TO
          completely_RB replaced_VBN nodes_NNS ._.
        
        
          MRI_NNP
          MRI_NNP was_VBD performed_VBN at_IN 1_CD ._. 5_CD T_NN (_( System_NNP 9_CD X_NNP ,_, General_NNP Electric_NNP Medical_NNP Systems_NNPS ,_, Milwaukee_NNP ,_,
          Wisconsin_NNP ,_, United_NNP States_NNPS )_) using_VBG phased-array_JJ coils_NNS ._. All_DT images_NNS were_VBD archived_JJ on_IN DICOM_NNP
          PACS_NNS servers_NNS (_( MIPortal_NNP ,_, CMIR_NNP and_CC Siemens_NNP Medical_NNP Systems_NNPS ,_, Erlangen_NNP ,_, Germany_NNP ;_: and_CC Impax_NNP RS_NNP
          3000_CD ,_, AGFA_NNP Technical_NNP Imaging_NNP Systems_NNPS ,_, Richfield_NNP Park_NNP ,_, New_NNP Jersey_NNP ,_, United_NNP States_NNPS )_) for_IN
          subsequent_JJ analysis_NN ._. Images_NNP of_IN the_DT pelvis_NNS (_(
          n_NN =_SYM 56_CD )_) extended_VBN from_IN the_DT pubic_JJ symphysis_NNS to_TO just_RB above_IN the_DT level_NN of_IN
          aortic_JJ bifurcation_NN ._. In_IN patients_NNS with_IN primary_JJ testicular_NN cancers_NNS (_(
          n_NN =_SYM 7_CD )_) imaging_NN was_VBD extended_VBN superiorly_RB to_TO include_VB the_DT renal_JJ hilum_NN and_CC
          retroperitoneum_NN ._. In_IN patients_NNS with_IN breast_NN cancer_NN (_(
          n_NN =_SYM 7_CD )_) we_PRP obtained_VBD MR_NNP images_NNS of_IN the_DT bilateral_JJ axillae_NN ,_, including_VBG the_DT
          internal_JJ mammary_JJ and_CC supraclavicular_NN regions_NNS ._. All_DT patients_NNS were_VBD imaged_JJ with_IN identical_JJ
          pulse_NN sequences_NNS and_CC timing_NN parameters_NNS ._. Imaging_NNP was_VBD performed_VBN before_IN and_CC 24_CD h_NN after_IN
          intravenous_JJ ferumoxtran-_NN 10_CD administration_NN (_( Combidex_NNP ,_, Advanced_NNP Magnetics_NNP ,_, Cambridge_NNP ,_,
          Massachusetts_NNP ,_, United_NNP States_NNPS ;_: 2_CD ._. 6_CD mg_NN Fe_NNP /_NN kg_NN diluted_VBN in_IN normal_JJ saline_NN and_CC infused_VBN over_IN a_DT
          20_CD -_: min_NN period_NN using_VBG a_DT 5_CD -_: μm_NN filter_NN )_) ._.
          The_DT acquired_VBN pulse_NN sequences_NNS included_VBD (_( a_DT )_) axial_NN T_NN 2_CD -_: weighted_JJ fast_RB spin-echo_JJ (_( TR_NNP /_NN TE_NNP ,_,
          4500_CD /_NN 80_CD ;_: flip_JJ angle_NN ,_, 90_CD °_NN ;_: field_NN of_IN view_NN ,_, 24_CD –_NN 28_CD cm_NN ;_: slice_NN thickness_NN ,_, 3_CD mm_NN ;_: matrix_NN ,_, 256_CD ×_NN
          256_CD ;_: number_NN of_IN excitations_NNS ,_, 2_CD ;_: in-plane_JJ resolution_NN ,_, 1_CD ._. 2_CD mm_NN )_) ;_: (_( b_SYM )_) a_DT T_NN 1_CD -_: weighted_JJ
          two-dimensional_JJ gradient-echo_JJ sequence_NN obtained_VBN in_IN different_JJ anatomical_JJ planes_NNS (_( TR_NNP /_NN TE_NNP
          175_CD /_NN 1_CD ._. 8_CD ;_: flip_JJ angle_NN ,_, 80_CD °_NN ;_: field_NN of_IN view_NN ,_, 22_CD –_NN 30_CD cm_NN ;_: slice_NN thickness_NN ,_, 4_CD mm_NN ;_: matrix_NN ,_, 128_CD ×_NN
          256_CD ;_: in-plane_JJ resolution_NN ,_, 2_CD ._. 0_CD mm_NN )_) ;_: (_( c_SYM )_) an_DT axial_NN T_NN 2_CD -_: weighted_JJ dual_JJ TE_NNP gradient-echo_JJ (_( TR_NNP /_NN TE_NNP
          2100_CD /_NN 14_CD –_NN 24_CD ;_: flip_JJ angle_NN ,_, 70_CD °_NN ;_: field_NN of_IN view_NN ,_, 26_CD –_NN 28_CD cm_NN ;_: slice_NN thickness_NN ,_, 3_CD mm_NN ;_: matrix_NN ,_, 160_CD
          ×_NN 256_CD ;_: in-plane_JJ resolution_NN ,_, 1_CD ._. 7_CD mm_NN )_) ;_: and_CC (_( d_SYM )_) a_DT three-dimensional_JJ (_( 3_CD D_NNP )_) T_NN 1_CD -_: weighted_JJ
          gradient_NN echo_VBP sequence_NN ;_: TR_NNP /_NN TE_NNP 4_CD ._. 5_CD –_NN 5_CD ._. 5_LS /_NN 1_CD ._. 4_LS ;_: flip_JJ angle_NN ,_, 15_CD °_NN ;_: field_NN of_IN view_NN ,_, 24_CD –_NN 28_CD cm_NN ;_:
          slice_NN thickness_NN ,_, 1_CD ._. 4_CD mm_NN ;_: matrix_NN ,_, 256_CD ×_NN 256_CD ;_: in-plane_JJ resolution_NN ,_, 1_CD ._. 0_CD mm_NN )_) ._.
          The_DT above_IN listed_VBN imaging_NN sequences_NNS and_CC parameters_NNS had_VBD previously_RB been_VBN optimized_JJ to_TO
          reduce_VB motion_NN artifacts_NNS ,_, maximize_VB signal-to-noise_JJ ratio_NN (_( SNR_NNP )_) ,_, and_CC provide_VB diagnostically_RB
          useful_JJ images_NNS of_IN the_DT pelvis_NNS ,_, abdomen_NN ,_, and_CC chest_NN within_IN clinically_RB acceptable_JJ time_NN limits_NNS ._.
          The_DT T_NN 2_CD -_: weighted_JJ fast_RB spin-echo_JJ sequence_NN ,_, in_IN (_( a_DT )_) above_IN ,_, was_VBD primarily_RB used_VBN for_IN qualitative_JJ
          nodal_NN detection_NN ,_, and_CC hence_RB a_DT square_JJ pixel_NN with_IN more_JJR than_IN one_CD acquisition_NN was_VBD obtained_VBN ._.
          The_DT two-dimensional_JJ axial_NN T_NN 1_CD -_: weighted_JJ gradient-echo_JJ sequence_NN ,_, in_IN (_( b_SYM )_) above_IN ,_, was_VBD chosen_VBN to_TO
          achieve_VB adequate_JJ anatomical_JJ coverage_NN within_IN a_DT short_JJ imaging_NN time_NN ._. The_DT axial_NN dual-echo_JJ
          gradient-echo_JJ sequence_NN ,_, in_IN (_( c_SYM )_) above_IN ,_, was_VBD developed_VBN specifically_RB for_IN this_DT project_NN to_TO
          provide_VB artifact-free_JJ datasets_NNS for_IN quantitative_JJ image_NN analysis_NN ._. A_DT matrix_NN size_NN of_IN 160_CD ×_NN
          256_CD was_VBD chosen_VBN for_IN this_DT sequence_NN to_TO achieve_VB a_DT balance_NN between_IN the_DT upper_JJ limits_NNS for_IN
          imaging_NN time_NN while_IN reducing_VBG image_NN noise_NN ._. Finally_RB ,_, a_DT 3_CD D_NNP T_NN 1_CD -_: weighted_JJ sequence_NN was_VBD obtained_VBN ,_,
          in_IN (_( d_SYM )_) above_IN to_TO provide_VB a_DT dataset_NN for_IN vascular_NN maximum_NN intensity_NN projection_NN (_( MIP_NNP )_)
          reconstructions_NNS ._.
        
        
          Quantitative_NNP Image_NN Analysis_NNP
          All_DT image_NN analysis_NN was_VBD performed_VBN on_IN archived_JJ DICOM_NNP images_NNS using_VBG different_JJ software_NN
          packages_NNS (_( e_SYM ._. g_SYM ._. ,_, custom-built_JJ software_NN such_JJ as_IN CMIR-Image_NNP ,_, MGH_NNP ,_, Boston_NNP ,_, Massachusetts_NNP ,_,
          United_NNP States_NNPS ;_: Syngo_NNP ,_, Siemens_NNP Medical_NNP Systems_NNPS ;_: Advantage_NNP Windows_NNP ,_, General_NNP Electric_NNP
          Medical_NNP Systems_NNPS )_) ._. Lymph_NNP nodes_NNS were_VBD identified_VBN by_IN readers_NNS who_WP manually_RB placed_VBN kernels_NNS onto_IN
          each_DT node_NN for_IN automated_VBN boundary_NN detection_NN and_CC calculation_NN of_IN nodal_NN dimensions_NNS and_CC
          volumes_NNS ._. The_DT thus_RB identified_VBN regions_NNS of_IN interest_NN (_( ROIs_NNP )_) encompassed_VBD the_DT entire_JJ lymph_NN node_NN
          (_( not_RB only_RB portions_NNS of_IN it_PRP )_) and_CC were_VBD used_VBN for_IN quantitative_JJ signal-intensity_JJ (_( SI_NNP )_)
          measurements_NNS (_( see_VB Table_NNP 2_LS )_) ._. Serial_JJ measurements_NNS of_IN nodal_NN dimensions_NNS on_IN different_JJ pulse_NN
          sequences_NNS or_CC time_NN points_NNS varied_VBD less_JJR than_IN 2_CD %_NN ._.
          A_DT number_NN of_IN quantitative_JJ tissue_NN parameters_NNS were_VBD calculated_VBN either_CC as_IN differences_NNS
          between_IN pre-_NN and_CC postcontrast_NN scans_VBZ (_( δ_NN )_) or_CC as_IN single-value_JJ analysis_NN on_IN postcontrast_NN scans_VBZ
          (_( see_VB Table_NNP 2_LS )_) ._. The_DT lymph_NN node_NN /_NN muscle_NN (_( LNM_NNP )_) ratio_NN was_VBD calculated_VBN by_IN dividing_VBG signal_NN
          intensities_NNS of_IN an_DT entire_JJ lymph_NN node_NN by_IN that_DT of_IN adjacent_JJ muscle_NN using_VBG a_DT similar-sized_JJ ROI_NNP ,_,
          drawn_VBN manually_RB ._. The_DT nodal_NN SI_NNP change_NN was_VBD calculated_VBN by_IN obtaining_VBG SI_NNP before_IN and_CC after_IN
          contrast_NN administration_NN ._. The_DT nodal_NN SNR_NNP was_VBD calculated_VBN by_IN obtaining_VBG SD_NNP /_NN SD_NNP
          noise_NN ._. The_DT T_NN 2_CD *_NN was_VBD calculated_VBN in_IN nodal_NN ROIs_NNP on_IN dual_JJ TE_NNP images_NNS using_VBG
          CMIR-Image_NNP ._. T_NN 2_CD *_NN maps_NNS were_VBD constructed_VBN by_IN performing_VBG fits_NNS of_IN a_DT standard_JJ exponential_NN
          relaxation_NN model_NN (_( S_NNP =_SYM Ke_NNP
          –_NN TE_NNP /_NN T_NN 2_CD *_NN )_) to_TO the_DT data_NNS on_IN a_DT pixel-by-pixel_JJ basis_NN ._. Only_RB pixels_NNS with_IN
          intensity_NN greater_JJR than_IN a_DT threshold_NN level_NN (_( 2_CD X_NNP of_IN noise_NN )_) were_VBD considered_VBN during_IN the_DT fitting_JJ
          process_NN ._. Pixel_NNP variance_NN was_VBD obtained_VBN from_IN post-_NN MR_NNP images_NNS ._. Comparative_NNP visual_JJ analysis_NN
          included_VBD short_JJ axis_NNS measurements_NNS ,_, and_CC identification_NN of_IN heterogeneity_NN ,_, large_JJ focal_JJ
          defects_NNS ,_, and_CC central_JJ hyperintensity_NN ,_, according_VBG to_TO criteria_NNS previously_RB established_VBN
          [_NN 12_CD ,_, 17_CD ]_NN ._.
          To_TO determine_VB the_DT diagnostic_JJ accuracy_NN of_IN the_DT different_JJ tissue_NN parameters_NNS in_IN the_DT
          learning_VBG dataset_NN ,_, we_PRP determined_VBD sensitivity_NN ,_, specificity_NN ,_, and_CC predictive_JJ values_NNS for_IN each_DT
          parameter_NN alone_RB and_CC in_IN combination_NN (_( Table_NNP 3_LS )_) ._. The_DT most_RBS discriminatory_JJ parameters_NNS were_VBD
          then_RB applied_VBN to_TO the_DT test_NN dataset_NN (_( Table_NNP 4_LS )_) ._.
          In_IN the_DT final_JJ set_NN of_IN semiautomated_JJ image_NN analysis_NN ,_, 3_CD D_NNP reconstructions_NNS were_VBD obtained_VBN for_IN
          nodal_NN mapping_NN onto_IN vascular_NN anatomy_NN using_VBG MIP_NNP projections_NNS ._. While_IN the_DT MIP_NNP projections_NNS do_VBP
          not_RB aid_VB in_IN the_DT differentiation_NN between_IN malignant_JJ and_CC benign_JJ lymph_NN nodes_NNS ,_, they_PRP are_VBP
          invaluable_JJ in_IN providing_VBG anatomic_JJ content_NN to_TO the_DT dozens_NNS of_IN lymph_NN nodes_NNS identified_VBN ._. In_IN
          particular_JJ ,_, MIP_NNP images_NNS were_VBD generated_VBN interactively_RB from_IN postcontrast_NN ,_, fat-saturated_JJ ,_,
          volumetric_JJ interpolated_JJ breath-hold_JJ images_NNS to_TO outline_VB vascular_NN anatomy_NN ._. The_DT evaluated_VBN
          lymph_NN nodes_NNS characterized_VBN as_IN benign_JJ or_CC malignant_JJ (_( by_IN T_NN 2_CD *_NN /_NN variance_NN analysis_NN )_) were_VBD then_RB
          superimposed_VBN on_IN the_DT volumetric_JJ 3_CD D_NNP images_NNS ,_, using_VBG customized_VBN software_NN (_( Advantage_NNP Windows_NNP ,_,
          General_NNP Electric_NNP Medical_NNP Systems_NNPS )_) ._.
        
        
          Statistical_NNP Analysis_NNP
          Data_NNP were_VBD expressed_VBN as_IN mean_NN ±_NN standard_JJ deviations_NNS (_( SD_NNP )_) and_CC medians_NNS ._. All_DT statistical_JJ
          testing_NN was_VBD performed_VBN using_VBG GraphPad_NNP Prism_NNP (_( GraphPad_NNP Software_NNP ,_, San_NNP Diego_NNP ,_, California_NNP ,_,
          United_NNP States_NNPS )_) ._. The_DT significance_NN between_IN two_CD individual_JJ groups_NNS was_VBD determined_VBN using_VBG the_DT
          nonpaired_JJ Student_NNP 's_POS 
          t_NN -_: test_NN (_( e_SYM ._. g_SYM ._. ,_, benign_JJ and_CC malignant_JJ datasets_NNS in_IN Figure_NN 1_LS )_) ._. For_IN the_DT more_RBR
          discriminatory_JJ datasets_NNS alternative-free-response_JJ receiver_NN operating_VBG characteristic_JJ
          curves_NNS were_VBD plotted_VBD ._. Ratios_NNP for_IN cut-off_JJ single-value_JJ parameters_NNS were_VBD defined_VBN to_TO yield_VB
          highest_JJS sensitivity_NN and_CC specificity_NN ._. Accuracy_NNP for_IN a_DT given_VBN parameter_NN was_VBD expressed_VBN as_IN the_DT
          area_NN under_IN the_DT curve_NN (_( A_DT
          z_SYM )_) ,_, and_CC values_NNS are_VBP summarized_VBD in_IN Table_NNP 4_CD ._.
        
        
          Histology_NNP
          All_DT lymph_NN nodes_NNS were_VBD sampled_VBN histologically_RB within_IN 2_CD wk_NN of_IN the_DT MRI_NNP (_( mean_VB :_: 6_CD d_SYM ;_: range_NN :_:
          2_CD –_NN 14_CD d_SYM )_) ._. The_DT analysis_NN was_VBD done_VBN in_IN surgically_RB resected_JJ lymph_NN nodes_NNS (_(
          n_NN =_SYM 55_CD ;_: both_DT benign_JJ and_CC malignant_JJ nodes_NNS )_) or_CC in_IN fine_NN needle_NN aspirates_NNS
          and_CC core_NN biopsies_NNS (_(
          n_NN =_SYM 15_CD ;_: malignant_JJ nodes_NNS only_RB )_) ,_, implementing_VBG careful_JJ mapping_NN procedures_NNS
          to_TO correlate_VBP nodes_NNS ._. Surgically_NNP excised_VBD nodes_NNS were_VBD sectioned_JJ at_IN 10_CD –_NN 20_CD μm_NN intervals_NNS after_IN
          bihalving_VBG and_CC were_VBD stained_JJ with_IN hematoxylin-eosin_JJ ._.
        
      
      
        Results_NNS
        
          Learning_NNP Dataset_NNP
          The_DT learning_VBG dataset_NN consisted_VBD of_IN 97_CD histologically_RB validated_JJ lymph_NN nodes_NNS from_IN 36_CD
          patients_NNS with_IN different_JJ primary_JJ malignancies_NNS (_( see_VB Table_NNP 1_LS )_) ._. The_DT mean_JJ short_JJ axis_NNS diameter_NN
          was_VBD 10_CD ._. 5_LS mm_NN (_( range_NN 3_CD –_NN 39_CD mm_NN )_) with_IN 56_CD of_IN the_DT 97_CD nodes_NNS (_( 58_CD ._. 3_LS %_NN )_) measuring_VBG less_JJR than_IN 10_CD mm_NN ,_,
          that_WDT is_VBZ ,_, below_IN the_DT traditional_JJ imaging_NN cutoff_NN for_IN malignancy_NN (_(“ occult_NN nodes_NNS” )_) ._. Table_NNP 2_CD
          summarizes_NNS the_DT incidence_NN of_IN different_JJ visual_JJ ,_, comparative_JJ (_( before_IN and_CC after_IN contrast_NN
          administration_NN )_) ,_, and_CC semiautomated_JJ (_( postcontrast_NN administration_NN only_RB )_) parameters_NNS in_IN the_DT
          two_CD different_JJ groups_NNS ._. Figure_NN 1_CD is_VBZ a_DT graphical_JJ representation_NN of_IN overlaps_NNS between_IN
          malignant_JJ and_CC benign_JJ groups_NNS for_IN different_JJ parameters_NNS listed_VBN in_IN Table_NNP 2_CD ._. Table_NNP 3_CD
          summarizes_NNS sensitivities_NNS ,_, specificities_NNS ,_, and_CC predictive_JJ values_NNS for_IN the_DT different_JJ
          quantitative_JJ imaging_NN parameters_NNS ._. Sensitivities_NNP of_IN metastasis_NNS detection_NN by_IN visual_JJ image_NN
          analysis_NN ranged_VBD from_IN 50_CD %_NN –_NN 94_CD %_NN ,_, however_RB ,_, often_RB with_IN lower_JJR specificities_NNS ._. Volumetric_NNP
          measurements_NNS ,_, in_IN particular_NN ,_, were_VBD insensitive_JJ markers_NNS of_IN malignancy_NN in_IN nonenlarged_JJ nodes_NNS
          (_( see_VB Table_NNP 3_LS )_) ._.
          In_IN contradistinction_NN ,_, image_NN analysis_NN of_IN pre-_NN and_CC postcontrast_NN image_NN sequences_NNS resulted_VBD
          in_IN higher_JJR specificities_NNS and_CC sensitivities_NNS (_( see_VB Table_NNP 3_LS )_) ._. Comparative_NNP differences_NNS between_IN
          benign_JJ and_CC malignant_JJ nodal_NN groups_NNS were_VBD highest_JJS for_IN T_NN 2_CD *_NN and_CC pixel_NN variance_NN measurements_NNS
          (_( see_VB Table_NNP 3_LS )_) ._. Of_IN all_PDT the_DT semiautomated_JJ parameters_NNS tested_VBN alone_RB ,_, T_NN 2_CD *_NN measurements_NNS showed_VBD
          the_DT highest_JJS sensitivity_NN (_( 93_CD %_NN ;_: 95_CD %_NN confidence_NN interval_NN :_: 82_CD %_NN –_NN 98_CD %_NN )_) and_CC specificity_NN (_( 94_CD %_NN ;_: 95_CD %_NN
          confidence_NN interval_NN :_: 84_CD %_NN –_NN 99_CD %_NN )_) in_IN the_DT learning_VBG dataset_NN (_( see_VB Figure_NN 1_CD and_CC Table_NNP 3_LS )_) ._.
          Of_IN all_PDT the_DT semiautomated_JJ parameters_NNS tested_VBN in_IN combination_NN ,_, T_NN 2_CD *_NN measurements_NNS combined_VBN
          with_IN pixel_NN variance_NN analyses_NNS postcontrast_NN showed_VBD the_DT highest_JJS sensitivity_NN (_( 98_CD %_NN ;_: 95_CD %_NN
          confidence_NN interval_NN :_: 88_CD %_NN –_NN 99_CD %_NN )_) and_CC specificity_NN (_( 94_CD %_NN ;_: 95_CD %_NN confidence_NN interval_NN :_: 82_CD %_NN –_NN 98_CD %_NN )_) in_IN
          the_DT learning_VBG dataset_NN (_( Figure_NN 1_CD E_NNP )_) ._. Using_VBG the_DT dual-value_JJ analysis_NN ,_, there_EX was_VBD one_CD malignant_JJ
          outlier_NN in_IN the_DT benign_JJ dataset_NN (_( the_DT lymph_NN node_NN was_VBD 3_CD mm_NN in_IN overall_JJ size_NN ,_, with_IN few_JJ
          malignant_JJ cells_NNS seen_VBN on_IN histology_NN ,_, and_CC probably_RB too_RB small_JJ for_IN analysis_NN )_) and_CC two_CD benign_JJ
          outliers_NNS in_IN the_DT malignant_JJ dataset_NN (_( both_DT these_DT nodes_NNS showed_VBD hyalinosis_NNS replacing_VBG more_JJR than_IN
          50_CD %_NN of_IN the_DT nodal_NN architecture_NN )_) ._.
        
        
          Test_NNP Dataset_NNP
          To_TO determine_VB whether_IN feature_NN extraction_NN would_MD be_VB accurate_JJ for_IN prospective_JJ nodal_NN
          staging_NN ,_, we_PRP utilized_JJ the_DT above_JJ criteria_NNS against_IN a_DT larger_JJR test_NN dataset_NN encompassing_VBG 216_CD
          validated_JJ lymph_NN nodes_NNS from_IN 34_CD patients_NNS ,_, including_VBG different_JJ primaries_NNS (_( see_VB Table_NNP 1_LS )_) ._. The_DT
          sensitivity_NN ,_, specificity_NN ,_, and_CC predictive_JJ values_NNS of_IN the_DT most_RBS discriminatory_JJ parameters_NNS of_IN
          this_DT prospective_JJ analysis_NN are_VBP summarized_VBD in_IN Table_NNP 4_CD ._. We_PRP primarily_RB focused_VBD on_IN
          semiautomated_JJ image_NN analysis_NN of_IN postcontrast_NN scans_VBZ because_IN of_IN the_DT high_JJ sensitivity_NN and_CC
          specificity_NN determined_VBN in_IN the_DT learning_VBG dataset_NN ._. T_NN 2_CD *_NN measurements_NNS showed_VBD a_DT sensitivity_NN of_IN
          (_( 93_CD %_NN ;_: 95_CD %_NN confidence_NN interval_NN :_: 82_CD %_NN –_NN 99_CD %_NN )_) and_CC a_DT specificity_NN of_IN (_( 91_CD %_NN ;_: 95_CD %_NN confidence_NN
          interval_NN :_: 85_CD %_NN –_NN 96_CD %_NN )_) ._. Combined_VBN T_NN 2_CD *_NN and_CC pixel_NN variance_NN analysis_NN achieved_VBD a_DT sensitivity_NN of_IN
          98_CD %_NN (_( 95_CD %_NN confidence_NN interval_NN :_: 88_CD %_NN –_NN 99_CD %_NN )_) and_CC a_DT specificity_NN of_IN 92_CD %_NN (_( 95_CD %_NN confidence_NN interval_NN :_:
          87_CD %_NN –_NN 96_CD %_NN )_) comparable_JJ to_TO that_DT of_IN the_DT learning_VBG set_VBN and_CC much_JJ superior_JJ to_TO currently_RB used_VBN size_NN
          criteria_NNS ._.
          Using_VBG the_DT dual-value_JJ analysis_NN ,_, there_EX were_VBD two_CD malignant_JJ outliers_NNS in_IN the_DT benign_JJ dataset_NN
          (_( both_DT of_IN these_DT nodes_NNS were_VBD less_JJR than_IN 3_CD mm_NN in_IN overall_JJ size_NN and_CC probably_RB too_RB small_JJ for_IN
          analysis—similar_NN to_TO the_DT learning_VBG dataset_NN )_) and_CC three_CD benign_JJ outliers_NNS in_IN the_DT malignant_JJ
          dataset_NN (_( two_CD of_IN these_DT nodes_NNS had_VBD hyalinosis_NNS replacing_VBG more_JJR than_IN 50_CD %_NN of_IN the_DT nodal_NN
          architecture_NN and_CC one_CD had_VBD macrocalcifications_NNS )_) ._. More_RBR important_JJ ,_, all_PDT the_DT misclassified_VBN
          nodes_NNS occurred_VBD in_IN individual_JJ patients_NNS rather_RB than_IN in_IN the_DT same_JJ patient_NN and_CC ,_, hence_RB ,_, did_VBD not_RB
          affect_VB the_DT overall_JJ nodal_NN staging_NN on_IN a_DT patient-by-patient_JJ basis_NN in_IN this_DT dataset_NN ._.
        
        
          Image_NN Reconstruction_NNP
          Utilizing_NNP semiautomated_JJ feature_NN extraction_NN to_TO identify_VB lymph_NN nodes_NNS and_CC image_NN analysis_NN
          (_( based_VBN on_IN T_NN 2_CD *_NN and_CC pixel_NN variance_NN )_) ,_, we_PRP subsequently_RB proceeded_VBD to_TO map_VB individual_JJ lymph_NN
          nodes_NNS onto_IN vascular_NN anatomy_NN in_IN the_DT different_JJ anatomic_JJ drainage_NN patterns_NNS ._. Figure_NN 2_CD
          summarizes_NNS the_DT different_JJ steps_NNS in_IN image_NN analysis_NN ._. Figure_NN 3_CD and_CC Video_NNP 1_CD shows_VBZ an_DT example_NN
          of_IN a_DT 45_CD -_: y-old_JJ patient_NN with_IN colorectal_NN cancer_NN undergoing_VBG semiautomated_JJ nodal_NN staging_NN ._. In_IN
          this_DT particular_JJ patient_NN ,_, MRI_NNP identified_VBD six_CD positive_JJ lymph_NN nodes_NNS (_( <_NN 10_CD mm_NN each_DT )_) ,_,
          reconstructed_VBD as_IN a_DT 3_CD D_NNP dataset_NN ,_, whereas_IN all_DT positive_JJ lymph_NN nodes_NNS were_VBD missed_VBN by_IN PET_NNP scans_VBZ ._.
          Figure_NN 4_CD and_CC Video_NNP 2_CD show_NN reconstructions_NNS and_CC analyses_NNS from_IN a_DT patient_NN with_IN a_DT breast_NN
          cancer_NN primary_JJ with_IN bilateral_JJ nodal_NN metastases_NNS ._. Note_VB the_DT high_JJ spatial_NN resolution_NN allowing_VBG
          the_DT detection_NN of_IN a_DT 3_CD -_: mm_NN nodal_NN metastasis_NNS ._.
        
      
      
        Discussion_NNP
        We_PRP show_VBP that_IN it_PRP is_VBZ feasible_JJ to_TO extract_VB various_JJ quantitative_JJ tissue_NN parameters_NNS to_TO predict_VB
        the_DT likelihood_NN of_IN nodal_NN metastases_NNS in_IN vivo_NN ._. These_DT results_NNS are_VBP highly_RB relevant_JJ in_IN cancer_NN
        staging_NN because_IN they_PRP provide_VBP evidence_NN that_IN (_( a_DT )_) quantitative_JJ tissue_NN parameters_NNS enable_VBP
        diagnosis_NN of_IN lymph_NN node_NN metastases_NNS while_IN reducing_VBG interobserver_NN variability_NN and_CC (_( b_SYM )_) that_IN
        semiautomated_JJ reconstructions_NNS allow_VBP spatially_RB more_RBR extensive_JJ mapping_NN than_IN is_VBZ currently_RB
        possible_JJ ._.
        Metastases_NNP to_TO lymph_NN nodes_NNS occur_VBP during_IN growth_NN of_IN most_JJS primary_JJ malignancies_NNS ,_, and_CC their_PRP$
        presence_NN mandates_VBZ the_DT need_NN for_IN more_RBR extensive_JJ and_CC systemic_JJ therapy_NN ._. Nodal_NNP cancer_NN staging_NN
        currently_RB relies_VBZ on_IN invasive_JJ procedures_NNS (_( surgical_JJ lymph_NN node_NN dissection_NN ,_, sentinel_NN lymph_NN
        node_NN resection_NN ,_, biopsy_NN )_) with_IN significant_JJ morbidity_NN and_CC cost_NN [_NN 22_CD ,_, 23_CD ]_NN ,_, or_CC insensitive_JJ
        tomographic_JJ imaging_NN methods_NNS [_NN 24_CD ]_NN ._. For_IN example_NN ,_, detection_NN sensitivities_NNS using_VBG size_NN criteria_NNS
        with_IN state-of-the-art_JJ multislice_NN CT_NNP are_VBP as_RB low_JJ as_IN 50_CD %_NN ,_, whereas_IN PET_NNP imaging_NN of_IN nonenlarged_JJ
        nodes_NNS has_VBZ equally_RB low_JJ sensitivities_NNS [_NN 14_CD ]_NN ._. Based_VBN on_IN the_DT observation_NN that_IN nanoparticulate_NN
        solutions_NNS accumulate_VBP in_IN nodal_NN macrophages_NNS upon_IN systemic_JJ injections_NNS [_NN 25_CD ,_, 26_CD ]_NN ,_, lymphotropic_JJ
        superparamagnetic_JJ preparations_NNS have_VBP been_VBN developed_VBN [_NN 16_CD ]_NN ._. In_IN earlier_JJR clinical_JJ trials_NNS (_( using_VBG
        lower_JJR spatial_NN resolution_NN sequences_NNS )_) ,_, metastases_NNS of_IN 1_CD –_NN 2_CD mm_NN have_VBP been_VBN detected_VBN [_NN 17_CD ]_NN ,_, whereas_IN
        as_RB few_JJ as_IN 1_CD ,_, 000_CD tumor_NN cells_NNS have_VBP been_VBN detected_VBN in_IN nodes_NNS in_IN experimental_JJ mouse_NN models_NNS [_NN 18_CD ]_NN ._.
        Despite_IN these_DT advances_NNS ,_, it_PRP has_VBZ been_VBN difficult_JJ to_TO acquire_VB images_NNS of_IN sufficiently_RB high_JJ
        resolution_NN and_CC to_TO derive_VB parameters_NNS to_TO automate_NN diagnosis_NN ._. The_DT data_NNS presented_VBN here_RB indicate_VBP
        that_IN unique_JJ magnetic_JJ parameters_NNS allow_VBP identification_NN of_IN nodal_NN metastases_NNS and_CC accurate_JJ 3_CD D_NNP
        reconstructions_NNS ,_, including_VBG surgically_RB inaccessible_JJ lymph_NN nodes_NNS ._.
        The_DT significance_NN of_IN the_DT above_JJ findings_NNS is_VBZ 3_CD -_: fold_VB ._. First_LS ,_, the_DT ability_NN to_TO directly_RB and_CC
        noninvasively_RB monitor_VB nodal_NN tumor_NN involvement_NN represents_VBZ a_DT powerful_JJ diagnostic_JJ tool_NN for_IN
        cancer_NN ._. Accurate_NNP staging_NN represents_VBZ the_DT cornerstone_NN for_IN triaging_VBG patients_NNS to_TO either_CC
        localized_JJ or_CC to_TO more_RBR aggressive_JJ and_CC systemic_JJ therapies_NNS ._. Second_JJ ,_, the_DT method_NN described_VBD here_RB
        was_VBD sensitive_JJ for_IN the_DT limited_JJ subsets_NNS of_IN primary_JJ cancers_NNS tested_VBN ._. It_PRP is_VBZ reasonable_JJ to_TO
        hypothesize_NN that_IN such_JJ analysis_NN could_MD be_VB applied_VBN to_TO staging_NN of_IN other_JJ common_JJ primaries_NNS ._. In_IN
        particular_JJ ,_, lung_NN ,_, colorectal_NN ,_, genitourinary_JJ ,_, and_CC head_NN and_CC neck_NN cancers_NNS could_MD benefit_VB from_IN
        this_DT staging_NN procedure_NN ._. In_IN addition_NN to_TO nodal_NN staging_NN ,_, the_DT nanoparticle-enhanced_JJ MRI_NNP can_MD
        also_RB be_VB used_VBN to_TO measure_VB microvascularity_NN in_IN primary_JJ tumors_NNS [_NN 27_CD ]_NN and_CC to_TO improve_VB the_DT
        detection_NN of_IN liver_NN metastases_NNS [_NN 28_CD ]_NN ._. Third_NNP ,_, our_PRP$ results_NNS are_VBP significant_JJ because_IN the_DT
        semiautomated_JJ staging_NN method_NN is_VBZ highly_RB accurate_JJ and_CC reduces_VBZ variability_NN in_IN visual_JJ image_NN
        analyses_NNS between_IN different_JJ observers_NNS ._.
        The_DT LMRI_NNP staging_NN technique_NN is_VBZ believed_VBN to_TO be_VB clinically_RB relevant_JJ in_IN several_JJ key_JJ areas_NNS ._.
        First_LS ,_, LMRI_NNP may_MD play_VB a_DT significant_JJ role_NN in_IN avoiding_VBG unnecessary_JJ surgeries_NNS ,_, that_WDT is_VBZ ,_, those_DT
        in_IN node-positive_JJ patients_NNS ._. Second_JJ ,_, since_IN LMRI_NNP can_MD detect_VB lymph_NN nodes_NNS outside_IN traditional_JJ
        surgical_JJ fields_NNS ,_, this_DT information_NN may_MD influence_VB surgical_JJ approaches_NNS ._. In_IN colorectal_NN cancer_NN ,_,
        LMRI_NNP may_MD provide_VB a_DT “ sentinel-node-like_JJ” guide_NN to_TO staging_NN ._. Third_NNP ,_, it_PRP is_VBZ likely_JJ that_IN LMRI_NNP
        would_MD be_VB useful_JJ to_TO identify_VB appropriate_JJ patients_NNS to_TO receive_VB neoadjuvant_NN chemotherapy_NN prior_RB
        to_TO surgery_NN ._. Currently_RB ,_, neoadjuvant_NN therapy_NN is_VBZ often_RB reserved_VBN for_IN postoperative_JJ patients_NNS ,_,
        once_RB the_DT nodal_NN status_NN has_VBZ been_VBN determined_VBN ._. Fourth_JJ ,_, LMRI_NNP may_MD be_VB particularly_RB useful_JJ to_TO guide_VB
        radiation_NN therapy_NN by_IN mapping_VBG the_DT complete_JJ nodal_NN status_NN onto_IN bony_NN and_CC vascular_NN landmarks_NNS ._.
        Finally_RB ,_, LMRI_NNP could_MD be_VB used_VBN to_TO avoid_VB invasive_JJ diagnostic_JJ procedures_NNS ,_, which_WDT are_VBP not_RB part_VB of_IN
        therapy_NN ._. For_IN example_NN ,_, LMRI_NNP could_MD replace_VB lymphangiography_NN ,_, mediastinoscopy_NN ,_, or_CC endoscopic_JJ
        ultrasound_NN for_IN nodal_NN staging_NN ._.
        Our_PRP$ findings_NNS have_VBP a_DT number_NN of_IN direct_JJ implications_NNS for_IN technology_NN development_NN and_CC in_IN
        clinical_JJ care_NN ._. Accurate_NNP measurements_NNS of_IN T_NN 2_CD *_NN relies_VBZ on_IN motion_NN artifact-free_JJ multiecho_NN pulse_NN
        sequences_NNS that_WDT are_VBP not_RB routinely_RB available_JJ on_IN clinical_JJ scanners_NNS at_IN spatial_NN resolutions_NNS
        required_VBN for_IN nodal_NN staging_NN ._. Such_JJ sequences_NNS will_MD have_VB to_TO be_VB implemented_VBN and_CC combined_VBN with_IN
        postprocessing_VBG tools_NNS to_TO simplify_VB and_CC semiautomate_NN analysis_NN ._. Similar_JJ software_NN approaches_NNS are_VBP
        already_RB used_VBN routinely_RB in_IN lung_NN nodule_NN characterization_NN [_NN 29_CD ]_NN or_CC screening_NN for_IN breast_NN cancers_NNS
        [_NN 30_CD ]_NN ._. We_PRP predict_VBP that_IN in_IN the_DT case_NN of_IN LMRI_NNP ,_, such_JJ automation_NN routines_NNS will_MD be_VB highly_RB
        specific_JJ ,_, given_VBN the_DT unique_JJ mechanism_NN of_IN image_NN contrast_NN ._. As_IN a_DT proof-of-principle_JJ ,_, we_PRP
        implemented_VBD approaches_NNS to_TO identify_VB ,_, segment_NN ,_, analyze_VB ,_, and_CC display_NN nodal_NN information_NN ._. While_IN
        the_DT current_JJ technology_NN is_VBZ already_RB highly_RB accurate_JJ ,_, we_PRP anticipate_VBP further_JJ improvements_NNS with_IN
        hardware_NN and_CC software_NN advances_NNS ._. We_PRP hope_VBP that_IN this_DT will_MD ultimately_RB translate_VB into_IN clinical_JJ
        practice_NN and_CC replace_VB unnecessary_JJ intervention_NN ._.
      
    
  
